Vanguard Group Inc Rani Therapeutics Holdings, Inc. Transaction History

Vanguard Group Inc

$5.97 Trillion
Q2 2025

A detailed history of Vanguard Group Inc transactions in Rani Therapeutics Holdings, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 799,679 shares of RANI stock, worth $2.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

799,679

Previous 799,679 -0.0%

Holding current value

$2.29 Million

Previous $1.01 Million 59.58%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	BUY	$1.25 - $1.85 $112,313 - $166,224	89,851 Added 12.66%	799,679 $1.01 Million
Q2 2024 Aug 13, 2024	BUY	$3.13 - $7.85 $76,763 - $192,521	24,525 Added 3.58%	709,828 $2.7 Million
Q1 2024 May 10, 2024	BUY	$2.98 - $3.8 $50,528 - $64,432	16,956 Added 2.54%	685,303 $2.13 Million
Q4 2023 Feb 14, 2024	SELL	$1.85 - $3.67 $1,372 - $2,723	-742 Reduced 0.11%	668,347 $2.22 Million
Q4 2022 Feb 10, 2023	BUY	$5.51 - $10.02 $99,791 - $181,472	18,111 Added 2.78%	669,089 $3.95 Million
Q3 2022 Nov 14, 2022	BUY	$8.23 - $12.4 $2.62 Million - $3.94 Million	317,849 Added 95.41%	650,978 $6.24 Million
Q2 2022 Aug 12, 2022	BUY	$8.0 - $14.25 $344,176 - $613,063	43,022 Added 14.83%	333,129 $3.44 Million
Q1 2022 May 13, 2022	BUY	$12.21 - $23.14 $55,689 - $105,541	4,561 Added 1.6%	290,107 $3.92 Million
Q4 2021 Feb 14, 2022	BUY	$16.09 - $35.0 $37,537 - $81,655	2,333 Added 0.82%	285,546 $4.67 Million
Q3 2021 Nov 12, 2021	BUY	$10.7 - $21.43 $3.03 Million - $6.07 Million	283,213 New	283,213 $5.05 Million

Others Institutions Holding RANI

# of Institutions

Shares Held

6.34M

Call Options Held

29.4K

Put Options Held

View Full List

About Rani Therapeutics Holdings, Inc.

Ticker RANI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,492,000
Market Cap $70M
Description
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed P...

More about RANI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Rani Therapeutics Holdings, Inc. Transaction History